Search Results

Displaying Results 126-150 of 461 "'EP'"

Jun 01, 2026, 08:59 ET FRONTERA COMPLETES DIVESTMENT OF ITS COLOMBIAN E&P ASSETS PORTFOLIO TO PAREX RESOURCES; POSITIONS ITSELF AS A STANDALONE INFRASTRUCTURE COMPANY ANNOUNCES RETURN OF CAPITAL DISTRIBUTION TO SHAREHOLDERS

content:https://www.prnewswire.com/news-releases/frontera-completes-divestment-of-its-colombian-ep-assets-portfolio-to-parex-resources-positions-itself-as-a-standalone-infrastructure-company-announces-return-of-capital-distribution-to-shareholders-302787096.htmlSOURCE

More news about: Frontera Energy Corporation


Jun 01, 2026, 08:00 ET GIGABYTE ra mắt dòng bo mạch chủ AORUS INFINITY X870E và X870 nhân kỷ niệm 40 năm tại COMPUTEX 2026

Turbo Mode 2.0, công nghệ ép xung tối ưu bởi AI độc quyền của GIGABYTE. Các bo mạch chủ này được trang bị một chip phần cứng tích hợp có nhiệm vụ theo dõi điều kiện hoạt động của hệ thống và trạng thái xử lý khối lượng công việc theo thời gian thực. Kết hợp cùng công cụ ép xung (OC) động được huấn luyện

More news about: GIGABYTE


Jun 01, 2026, 07:00 ET Thesis Gold & Silver Strengthens Team with Appointment of Dimitry Demianyuk as EVP Project Development

June 1, 2026 /PRNewswire/ - Thesis Gold & Silver Inc. ("Thesis", or the "Company") (TSXV: TAU) (OTCQX: THSGF) (WKN: A3EP87) is pleased to announce the appointment of Mr. Dimitry Demianyuk as Executive Vice President, Project Development, effective June 21, 2026.

More news about: Thesis Gold & Silver Inc.


Jun 01, 2026, 04:30 ET EZVIZ brings up a new smart entry solution with the EP8 Ultra video doorbell, upgrading doorways with dual-lens technology and an interactive screen

GTM lead of the product line at EZVIZ. "With the EP8 Ultra, we want users to enjoy hassle-free protection delivered with thoughtful care, experiencing the tangible benefits rather than cold innovations driven by local AI."Prioritizing safety, the EP8 Ultra addresses the limited view at entrances.

More news about: EZVIZ


May 30, 2026, 00:29 ET 2026 ASCO | 富馬酸侖博替尼(A400/EP0031)治療RET融合陽性NSCLC的關鍵研究數據發佈

2026年5月30日 /美通社/ -- 2026年5月30日,四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」,6990.HK)宣佈,在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上,廣東省人民醫院周清教授以口頭報告形式公佈了新一代選擇性轉染過程中重排(RET)抑制劑富馬酸侖博替尼(A400/EP0031,寧泰萊®[1])用於治療晚期RET融合陽性非小細胞肺癌(NSCLC)的關鍵II期研究結果(摘要編號#8505,肺癌—轉移性非小細胞)。基於此項研究結果,富馬酸侖博替尼用於治療RET融合陽性的局部晚期或轉移性NSCLC成人患者的新藥上市申請(NDA)已獲中國國家藥品監督管理局(NMPA)受理。

More news about: 科倫博泰


May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral

More news about: Kelun-Biotech


May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

carcinoma (EP-NEC).As the first 4-1BB–targeting bispecific antibody globally to advance to a single-arm pivotal trial as monotherapy, Opamtistomig has been evaluated in 13 solid tumor indications in China, including 1 pivotal registration trial and 8 proof-of-concept studies. These cover EP-NEC, NSCLC,

More news about: Nanjing Leads Biolabs Co., Ltd.


May 27, 2026, 10:00 ET Fidelis Care Urges Essential Plan 200-250 Members to Take Action to Stay Covered

fideliscare.org/ep-changes for resources and enrollment support.About Fidelis CareFidelis Care is a mission-driven health plan offering quality,

More news about: Fidelis Care


May 27, 2026, 08:00 ET Minaris Expands Rapid Mycoplasma Detection Services with bioMérieux's BIOFIRE® Platform to Reduce Turnaround Time for Release and In-Process Testing

testing using BIOFIRE® Mycoplasma from bioMérieux Mycoplasma DNA Detection by MycoSEQ™ Plus from Thermo FisherTraditional compendial (EP/JP/USP) culture-based mycoplasma detection (GMP)This expanded capability builds on Minaris' years of experience with both PCR- and culture-based

More news about: Minaris Advanced Therapies, LLC


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.